Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)

2026-02-06 22:37:02 ET

Overview

Roivant’s ( ROIV ) stock is up 18% this morning after its subsidiary, Priovant Therapeutics, reported Phase 2 BEACON data in cutaneous sarcoidosis. Bear in mind that Roivant owns ~74% of Priovant–with Pfizer ( PFE ) nearly owning the rest. The drug in focus is brepocitinib, which is described as a “dual TYK2/JAK1 inhibitor administered as a once-daily oral therapy.” This one is actually being tested in a few conditions–including dermatomyositis (NDA submission planned) and non-infectious uveitis (Phase 3 ongoing)....

Read the full article on Seeking Alpha

For further details see: